Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity

Summary: Toll‐like receptors (TLRs) detect infections by highly conserved components of pathogens that are either not present in our own cells or are normally sequestered in cellular compartments that are inaccessible to the TLRs. Most TLRs are expressed on the cell surface, where they have been shown to detect pathogen‐expressed molecules such as lipopolysaccharides and lipopeptides. A subset of TLRs, including TLR3, TLR7, TLR8, and TLR9, are expressed intracellularly within one or more endosomal compartments and detect nucleic acids. Because pathogen and host nucleic acids have very similar structures, these endosomal TLRs may face an extra challenge to induce anti‐pathogen immune responses while avoiding the induction of autoimmune diseases. With the rapid growth in understanding of the biology of the TLRs has come an increasing awareness of their effects on autoimmunity, several aspects of which are the focus of this review. First, recent studies have revealed an inappropriate activation of TLR7, TLR8, and TLR9 in systemic lupus erythematosus and several other autoimmune diseases. Secondly, the potential for therapeutic development of TLR antagonists is considered. Finally, with the rapid progress in the development of therapeutic agonists for the TLRs, there is accompanying attention to the theoretical possibility that such therapy may induce autoimmunity or autoimmune diseases.

[1]  L. Audoly,et al.  Corrigendum: Toll-like receptor 9—dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.

[2]  H. Anders,et al.  Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. , 2007, Journal of the American Society of Nephrology : JASN.

[3]  S. Akira,et al.  Murine Dendritic Cell Type I IFN Production Induced by Human IgG-RNA Immune Complexes Is IFN Regulatory Factor (IRF)5 and IRF7 Dependent and Is Required for IL-6 Production1 , 2007, The Journal of Immunology.

[4]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[5]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[6]  T. Mayadas,et al.  Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. , 2007, Seminars in nephrology.

[7]  V. Hornung,et al.  Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. , 2007, Blood.

[8]  L. Audoly,et al.  Regulation of TLR9 dependent DNA Immune complex mediated cell activation by High Mobility Group Box Protein 1 (HMGB1) and Receptor for Advanced Glycation End products (RAGE) (128.35) , 2007, Journal of Immunology.

[9]  A. Iwasaki,et al.  In Brief , 2007, Nature Reviews Immunology.

[10]  D. Busch,et al.  Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. , 2007, International immunology.

[11]  S. Boulo,et al.  Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes. , 2007, Virus research.

[12]  Shizuo Akira,et al.  Antiviral signaling through pattern recognition receptors. , 2006, Journal of biochemistry.

[13]  Jianyong Wang,et al.  The Functional Effects of Physical Interactions among Toll-like Receptors 7, 8, and 9* , 2006, Journal of Biological Chemistry.

[14]  H. Anders,et al.  Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  S. Akira,et al.  Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides , 2006, European journal of immunology.

[16]  J. Battiste,et al.  Oligodeoxynucleotides Differentially Modulate Activation of TLR7 and TLR8 by Imidazoquinolines , 2006, The Journal of Immunology.

[17]  Yu-Tseung Liu,et al.  Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells , 2006, Nature Cell Biology.

[18]  John P. Vasilakos,et al.  Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides , 2006, The Journal of Immunology.

[19]  M. Madaio,et al.  Modulation of Autoimmunity by TLR9 in the Chronic Graft-vs-Host Model of Systemic Lupus Erythematosus1 , 2006, The Journal of Immunology.

[20]  Douglas T. Golenbock,et al.  Flavivirus Activation of Plasmacytoid Dendritic Cells Delineates Key Elements of TLR7 Signaling beyond Endosomal Recognition1 , 2006, The Journal of Immunology.

[21]  Gunther Hartmann,et al.  5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.

[22]  A. Pichlmair,et al.  RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.

[23]  C. Tsatsanis,et al.  Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. , 2006, Arthritis and rheumatism.

[24]  A. Marshak‐Rothstein Toll-like receptors in systemic autoimmune disease , 2006, Nature Reviews Immunology.

[25]  K. Ishii,et al.  Innate immune recognition of, and regulation by, DNA. , 2006, Trends in immunology.

[26]  D. Jarrossay,et al.  Distinct expression pattern of IFN-α and TNF-α in juvenile idiopathic arthritis synovial tissue , 2006 .

[27]  R. Coffman,et al.  Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.

[28]  R. Lafyatis,et al.  Antimalarial agents: closing the gate on Toll-like receptors? , 2006, Arthritis and rheumatism.

[29]  H. Anders,et al.  Microbial nucleic acids pay a Toll in kidney disease. , 2006, American journal of physiology. Renal physiology.

[30]  T. Ghosh,et al.  Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. , 2006, Cellular immunology.

[31]  J. Shupe,et al.  Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. , 2006, Immunity.

[32]  S. Akira,et al.  Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. , 2006, The Journal of clinical investigation.

[33]  H. Hackstein,et al.  TLR7 Ligands Induce Higher IFN-α Production in Females1 , 2006, The Journal of Immunology.

[34]  T. Winkler,et al.  Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. , 2006, International immunology.

[35]  C. McCaig,et al.  Expression of the human PAC1 receptor leads to dose-dependent hydrocephalus-related abnormalities in mice. , 2006, The Journal of clinical investigation.

[36]  G. Cheng,et al.  TLR Activation of Langerhans Cell-Like Dendritic Cells Triggers an Antiviral Immune Response1 , 2006, The Journal of Immunology.

[37]  Marion Jurk,et al.  Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T‐rich phosphorothiate oligodeoxynucleotides , 2006, European journal of immunology.

[38]  Quanzhen Li,et al.  A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Satterthwaite,et al.  Autoreactive B Cell Responses to RNA-Related Antigens Due to TLR7 Gene Duplication , 2006, Science.

[40]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[41]  H. Rammensee,et al.  Genetic Vaccines and Therapy , 2006 .

[42]  M. Sioud Single‐stranded small interfering RNA are more immunostimulatory than their double‐stranded counterparts: A central role for 2′‐hydroxyl uridines in immune responses , 2006, European journal of immunology.

[43]  R. Ashman,et al.  Extended sequence preferences for oligodeoxyribonucleotide activity , 2006, Immunology.

[44]  C. Lucchesi,et al.  Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Becher,et al.  Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. , 2006, The Journal of clinical investigation.

[46]  J. Langley,et al.  Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. , 2006, Vaccine.

[47]  J. Vollmer TLR9 in Health and Disease , 2006, International reviews of immunology.

[48]  D. Busch,et al.  Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO , 2006, European journal of immunology.

[49]  S. Akira,et al.  Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8 , 2005, The Journal of experimental medicine.

[50]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[51]  S. Su,et al.  Essential Role of the MyD88 Pathway, but Nonessential Roles of TLRs 2, 4, and 9, in the Adjuvant Effect Promoting Th1-Mediated Autoimmunity , 2005, The Journal of Immunology.

[52]  S. Akira,et al.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.

[53]  A. DeFranco,et al.  TLR3 and TLR7 Are Targeted to the Same Intracellular Compartments by Distinct Regulatory Elements*♦ , 2005, Journal of Biological Chemistry.

[54]  B. Baban,et al.  Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling1 , 2005, The Journal of Immunology.

[55]  S. Akira,et al.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[56]  F. Weber,et al.  Activation of Innate Defense against a Paramyxovirus Is Mediated by RIG-I and TLR7 and TLR8 in a Cell-Type-Specific Manner , 2005, Journal of Virology.

[57]  C. Hofmann,et al.  CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. , 2005, Gastroenterology.

[58]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[59]  L. Joosten,et al.  The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. , 2005, Arthritis and rheumatism.

[60]  S. Akira,et al.  Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus , 2005, The Journal of experimental medicine.

[61]  M. Sioud Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. , 2005 .

[62]  W. Falk,et al.  In vivo CpG DNA/toll-like receptor 9 interaction induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis , 2005, Gut.

[63]  M. Kretzler,et al.  Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. , 2005, Journal of the American Society of Nephrology : JASN.

[64]  M. Peterson,et al.  Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. , 2005, Arthritis and rheumatism.

[65]  J. Lesher,et al.  Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia. , 2005, Journal of the American Academy of Dermatology.

[66]  D. Klinman,et al.  Suppressive Oligodeoxynucleotides Protect Mice from Lethal Endotoxic Shock1 , 2005, The Journal of Immunology.

[67]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[68]  L. Eckmann,et al.  Amendment history : Corrigendum ( April 2005 ) Toll-like receptor 9 – induced type I IFN protects mice from experimental colitis , 2018 .

[69]  D. Speiser,et al.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. , 2005, The Journal of clinical investigation.

[70]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[71]  K. Ishii,et al.  Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. , 2005, Arthritis and rheumatism.

[72]  J. Bach A Toll-like trigger for autoimmune disease , 2005, Nature Medicine.

[73]  M. Tomai,et al.  Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.

[74]  S. Akira,et al.  Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease , 2005, Nature Medicine.

[75]  J. Friedberg,et al.  Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. , 2005, Blood.

[76]  P. Pietschmann,et al.  Rheumatoid arthritis synovium contains plasmacytoid dendritic cells , 2005, Arthritis research & therapy.

[77]  P. Gregersen,et al.  The emerging role of interferon in human systemic lupus erythematosus. , 2004, Current opinion in immunology.

[78]  S. Agrawal,et al.  Antisense and siRNA as agonists of Toll-like receptors , 2004, Nature Biotechnology.

[79]  A. Krieg,et al.  Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist , 2004, Journal of immunotherapy.

[80]  H. Gollnick,et al.  Androgen receptor status in lesional and normal skin of patients with rosacea , 2004, Journal of the European Academy of Dermatology and Venereology : JEADV.

[81]  C. Cooper,et al.  CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.

[82]  Angela Panoskaltsis-Mortari,et al.  Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.

[83]  J. Metzger,et al.  Toll‐like receptor 9 binds single‐stranded CpG‐DNA in a sequence‐ and pH‐dependent manner , 2004, European journal of immunology.

[84]  S. Young,et al.  U1 RNA induces innate immunity signaling. , 2004, Arthritis and rheumatism.

[85]  Y. Li,et al.  Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. , 2004, Vaccine.

[86]  D. Pisetsky,et al.  Release of DNA from Dead and Dying Lymphocyte and Monocyte Cell Lines In Vitro , 2004, Scandinavian journal of immunology.

[87]  J. LaManna,et al.  The Third Signal in T Cell-Mediated Autoimmune Disease?1 , 2004, The Journal of Immunology.

[88]  L. Rönnblom,et al.  Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.

[89]  A. DeFranco,et al.  Ligand-regulated Chimeric Receptor Approach Reveals Distinctive Subcellular Localization and Signaling Properties of the Toll-like Receptors* , 2004, Journal of Biological Chemistry.

[90]  Akiko Iwasaki,et al.  Recognition of single-stranded RNA viruses by Toll-like receptor 7. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[91]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[92]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[93]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[94]  John J Rossi,et al.  Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase , 2004, Nature Biotechnology.

[95]  L. Wen,et al.  The Effect of Innate Immunity on Autoimmune Diabetes and the Expression of Toll-Like Receptors on Pancreatic Islets1 , 2004, The Journal of Immunology.

[96]  H. Rammensee,et al.  Immunostimulating capacities of stabilized RNA molecules , 2004, European journal of immunology.

[97]  S. Akira,et al.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration , 2004, Nature Medicine.

[98]  R. DeMatteo,et al.  Liver Dendritic Cells Are Less Immunogenic Than Spleen Dendritic Cells because of Differences in Subtype Composition1 , 2004, The Journal of Immunology.

[99]  Hongsheng Wang,et al.  Impaired Clearance of Apoptotic Cells Induces the Activation of Autoreactive Anti-Sm Marginal Zone and B-1 B Cells 1 , 2004, The Journal of Immunology.

[100]  R. Coffman,et al.  IMMUNOBIOLOGY: IL-10 Regulates Plasmacytoid Dendritic Cell Response to CpG Containing ImmunoStimulatory Sequences , 2003 .

[101]  T. Utsugi,et al.  CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. , 2003, Immunity.

[102]  K. Lamberth,et al.  Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross‐reactive, natural HBsAg variants , 2003, European journal of immunology.

[103]  M. Shlomchik,et al.  Activation of autoreactive B cells by CpG dsDNA. , 2003, Immunity.

[104]  Lukas Hunziker,et al.  Dendritic cell–induced autoimmune heart failure requires cooperation between adaptive and innate immunity , 2003, Nature Medicine.

[105]  S. Akira,et al.  The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily , 2003, European journal of immunology.

[106]  W. Falk,et al.  Contrasting activity of cytosin–guanosin dinucleotide oligonucleotides in mice with experimental colitis , 2003, Clinical and experimental immunology.

[107]  K. Hasegawa,et al.  Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase in NZB ×NZWF1 mice , 2003, Lupus.

[108]  M. Crow Interferon-α: A new target for therapy in systemic lupus erythematosus? , 2003 .

[109]  G. Stark,et al.  SIGIRR, a negative regulator of Toll-like receptor–interleukin 1 receptor signaling , 2003, Nature Immunology.

[110]  R. Tisch,et al.  More Stringent Conditions of Plasmid DNA Vaccination Are Required to Protect Grafted Versus Endogenous Islets in Nonobese Diabetic Mice 1 , 2003, The Journal of Immunology.

[111]  S. Halperin,et al.  A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. , 2003, Vaccine.

[112]  C. Goodnow,et al.  Resistance to CpG DNA–induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling , 2003, Nature Immunology.

[113]  K. Ishii,et al.  Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. , 2003, Arthritis and rheumatism.

[114]  A. Krieg,et al.  CpG-A-Induced Monocyte IFN-γ-Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α1 , 2003, The Journal of Immunology.

[115]  J. Hardin Directing Autoimmunity to Nucleoprotein Particles , 2003, The Journal of experimental medicine.

[116]  R. Gay,et al.  Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. , 2003, Arthritis and rheumatism.

[117]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[118]  C. Cohen,et al.  Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. , 2003, Journal of the American Society of Nephrology : JASN.

[119]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[120]  Jae-Geun Yoon,et al.  CpG DNA Induces Self and Cross-Hyporesponsiveness of RAW264.7 Cells in Response to CpG DNA and Lipopolysaccharide: Alterations in IL-1 Receptor-Associated Kinase Expression1 , 2003, The Journal of Immunology.

[121]  G. Trinchieri,et al.  Flexibility of Mouse Classical and Plasmacytoid-derived Dendritic Cells in Directing T Helper Type 1 and 2 Cell Development , 2003, The Journal of experimental medicine.

[122]  A. Krieg CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both? , 2003, Scandinavian journal of infectious diseases.

[123]  T. Bieber,et al.  Successful Treatment of Chronic Discoid Lupus erythematosus of the Scalp with Imiquimod , 2002, Dermatology.

[124]  T. Nichterlein,et al.  CpG‐ODN‐induced inflammation is sufficient to cause T‐cell‐mediated autoaggression against hepatocytes , 2002, European journal of immunology.

[125]  I. Cohen,et al.  DNA Vaccination with Heat Shock Protein 60 Inhibits Cyclophosphamide-Accelerated Diabetes1 , 2002, The Journal of Immunology.

[126]  K. Ishii,et al.  Effect of Suppressive DNA on CpG-Induced Immune Activation1 , 2002, The Journal of Immunology.

[127]  K. Hasegawa,et al.  CpG oligodeoxynucleotides accelerate reovirus type 2‐triggered insulitis in DBA/1 suckling mice , 2002, International journal of experimental pathology.

[128]  B. Segal,et al.  Activation of APCs Through CD40 or Toll-Like Receptor 9 Overcomes Tolerance and Precipitates Autoimmune Disease1 , 2002, The Journal of Immunology.

[129]  Lin Chen,et al.  CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease , 2002, Neuroscience Letters.

[130]  J. Charles Jennette,et al.  Delayed Apoptotic Cell Clearance and Lupus-like Autoimmunity in Mice Lacking the c-mer Membrane Tyrosine Kinase , 2002, The Journal of experimental medicine.

[131]  J. Schölmerich,et al.  CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium‐treated mice , 2002, European journal of immunology.

[132]  S. Akira,et al.  Interferon-α and Interleukin-12 Are Induced Differentially by Toll-like Receptor 7 Ligands in Human Blood Dendritic Cell Subsets , 2002, The Journal of experimental medicine.

[133]  H. Wagner,et al.  Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 , 2002, Nature Immunology.

[134]  A. Gillum,et al.  Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. , 2002, Antisense & nucleic acid drug development.

[135]  K. Heeg,et al.  Immunostimulatory CpG-DNA Activates Murine Microglia1 , 2002, The Journal of Immunology.

[136]  Jae-Geun Yoon,et al.  Role of Mitogen-Activated Protein Kinases in CpG DNA-Mediated IL-10 and IL-12 Production: Central Role of Extracellular Signal-Regulated Kinase in the Negative Feedback Loop of the CpG DNA-Mediated Th1 Response1 , 2002, The Journal of Immunology.

[137]  Jongdae Lee,et al.  Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. , 2002, Gastroenterology.

[138]  A. Krieg A role for Toll in autoimmunity , 2002, Nature Immunology.

[139]  T. Giese,et al.  Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1 , 2002, The Journal of Immunology.

[140]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[141]  P. Godowski,et al.  Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines , 2002, The Journal of Immunology.

[142]  Michel C. Nussenzweig,et al.  Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[143]  G. Firestein,et al.  References Subscriptions Permissions Email Alerts Immunostimulatory DNA Sequences Influence the Course of Adjuvant Arthritis , 2013 .

[144]  L. Rönnblom,et al.  A Pivotal Role for the Natural Interferon α–producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus , 2001, The Journal of experimental medicine.

[145]  L. Rönnblom,et al.  Importance of CpG Dinucleotides in Activation of Natural IFN‐α‐Producing Cells by a Lupus‐Related Oligodeoxynucleotide , 2001, Scandinavian journal of immunology.

[146]  Virginia Pascual,et al.  Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus , 2001, Science.

[147]  A. Tarkowski,et al.  Intracisternally Localized Bacterial DNA Containing CpG Motifs Induces Meningitis1 , 2001, The Journal of Immunology.

[148]  I. Julkunen,et al.  IFNs activate toll-like receptor gene expression in viral infections , 2001, Genes and Immunity.

[149]  N. Kadowaki,et al.  Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.

[150]  C. Whitacre Sex differences in autoimmune disease , 2001, Nature Immunology.

[151]  M. V. von Herrath,et al.  Plasmid Vaccination with Insulin B Chain Prevents Autoimmune Diabetes in Nonobese Diabetic Mice1 , 2001, The Journal of Immunology.

[152]  T. Giese,et al.  Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. , 2001, European journal of immunology.

[153]  J. Portanova,et al.  CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. , 2001, International immunology.

[154]  T. Horiuchi,et al.  Mutation of DNASE1 in people with systemic lupus erythematosus , 2001, Nature Genetics.

[155]  A. Krieg,et al.  CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. , 2001, Antisense & nucleic acid drug development.

[156]  S. Akira,et al.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[157]  P. Payette,et al.  CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice , 2001, Journal of Virology.

[158]  V. Hornung,et al.  Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells , 2001 .

[159]  K. Heeg,et al.  Suppressors of Cytokine Signaling (SOCS)-1 and SOCS-3 Are Induced by CpG-DNA and Modulate Cytokine Responses in APCs1 , 2001, The Journal of Immunology.

[160]  R. Scott,et al.  Phagocytosis and clearance of apoptotic cells is mediated by MER , 2001, Nature.

[161]  J. Ellwart,et al.  Bacterial CpG-DNA Triggers Activation and Maturation of Human CD11c−, CD123+ Dendritic Cells1 , 2001, The Journal of Immunology.

[162]  N. Kadowaki,et al.  Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double-Stranded RNA, Respectively, Stimulate CD11c− Type 2 Dendritic Cell Precursors and CD11c+ Dendritic Cells to Produce Type I IFN1 , 2001, The Journal of Immunology.

[163]  J. Schwab,et al.  Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides , 2001, Journal of Neuroimmunology.

[164]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[165]  Asaf Rotem,et al.  Vaccination with Empty Plasmid DNA or CpG Oligonucleotide Inhibits Diabetes in Nonobese Diabetic Mice: Modulation of Spontaneous 60-kDa Heat Shock Protein Autoimmunity1 , 2000, The Journal of Immunology.

[166]  R. Kasukawa,et al.  Unmethylated oligo-DNA containing CpG motifs aggravates collagen-induced arthritis in mice. , 2000, Arthritis and rheumatism.

[167]  A. Tarkowski,et al.  The major role of macrophages and their product tumor necrosis factor alpha in the induction of arthritis triggered by bacterial DNA containing CpG motifs. , 2000, Arthritis and rheumatism.

[168]  L. Rönnblom,et al.  The Combination of Apoptotic U937 Cells and Lupus IgG Is a Potent IFN-α Inducer3 , 2000, The Journal of Immunology.

[169]  D. Isenberg,et al.  Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. , 2000, Arthritis and rheumatism.

[170]  John T. Chang,et al.  CpG Oligonucleotides Are Potent Adjuvants for the Activation of Autoreactive Encephalitogenic T Cells In Vivo , 2000, The Journal of Immunology.

[171]  T. Möröy,et al.  Features of systemic lupus erythematosus in Dnase1-deficient mice , 2000, Nature Genetics.

[172]  K. Mokhtari,et al.  Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[173]  V. Kouskoff,et al.  T cell-independent rescue of B lymphocytes from peripheral immune tolerance. , 2000, Science.

[174]  A. Krieg Minding the Cs and Gs. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[175]  A. Tarkowski,et al.  The features of arthritis induced by CpG motifs in bacterial DNA. , 2000, Arthritis and rheumatism.

[176]  R. Purcell,et al.  Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[177]  L. Rönnblom,et al.  Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. , 1999, Journal of immunology.

[178]  Lin Chen,et al.  Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. , 1999, Cancer research.

[179]  G. Hartmann,et al.  CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[180]  M. V. von Herrath,et al.  DNA immunization to prevent autoimmune diabetes. , 1999, The Journal of clinical investigation.

[181]  L. Strekowski,,et al.  Structure-activity relationship analysis of substituted 4-quinolinamines, antagonists of immunostimulatory CpG-oligodeoxynucleotides. , 1999, Bioorganic & medicinal chemistry letters.

[182]  Andrej Tarkowski,et al.  Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis , 1999, Nature Medicine.

[183]  P. Butler,et al.  Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity , 1999, Nature Medicine.

[184]  J. Penninger,et al.  Chlamydia infections and heart disease linked through antigenic mimicry. , 1999, Science.

[185]  L. Hültner,et al.  Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. , 1999, Journal of immunology.

[186]  T. Yamamoto,et al.  How BCG led to the discovery of immunostimulatory DNA. , 1999, Japanese journal of infectious diseases.

[187]  L. Steinman,et al.  Non-coding plasmid DNA induces IFN-γ in vivo and suppresses autoimmune encephalomyelitis , 1999 .

[188]  R. Kasukawa,et al.  CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. , 1999, The Journal of rheumatology.

[189]  A. Levin,et al.  Correlation of Toxicity and Pharmacokinetic Properties of a Phosphorothioate Oligonucleotide Designed to Inhibit ICAM-1 , 1999, Toxicologic pathology.

[190]  K. Conzelmann Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. , 1998, Annual review of genetics.

[191]  M. Hadchouel,et al.  Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. , 1998, Journal of immunology.

[192]  H. Mischak,et al.  CpG‐DNA‐specific activation of antigen‐presenting cells requires stress kinase activity and is preceded by non‐specific endocytosis and endosomal maturation , 1998, The EMBO journal.

[193]  A. Krieg,et al.  Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. , 1998, Journal of immunology.

[194]  D. Pisetsky,et al.  Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. , 1998, Journal of immunology.

[195]  T. Wu,et al.  Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[196]  R. Voll,et al.  Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. , 1998, Arthritis and rheumatism.

[197]  A. Krieg,et al.  CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. , 1998, Journal of immunology.

[198]  Pier Paolo Pandolfi,et al.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.

[199]  L. Manzel,et al.  Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. , 1998, Journal of immunology.

[200]  J. Piette,et al.  Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. , 1997, Arthritis and rheumatism.

[201]  S. Agrawal,et al.  Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. , 1997, Antisense & nucleic acid drug development.

[202]  E. Shevach,et al.  Microbial products induce autoimmune disease by an IL-12-dependent pathway. , 1997, Journal of immunology.

[203]  S L Hoffman,et al.  Do DNA vaccines induce autoimmune disease? , 1997, Human gene therapy.

[204]  D. Klinman,et al.  Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. , 1996, Journal of immunology.

[205]  H. Davis,et al.  DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[206]  D. Pisetsky,et al.  Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA , 1996, The Journal of experimental medicine.

[207]  G. Bishop,et al.  CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.

[208]  D. Pisetsky,et al.  Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. , 1991, Journal of immunology.

[209]  H. Pircher,et al.  Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice , 1991, Cell.

[210]  C. Steinman,et al.  Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. , 1990, The Journal of clinical investigation.

[211]  D. Jarrossay,et al.  Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue. , 2007, Rheumatology.

[212]  R. Medzhitov,et al.  Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA , 2006, Nature Immunology.

[213]  S. Peng,et al.  Toll-like receptor 9 signaling protects against murine lupus. , 2006, Arthritis and rheumatism.

[214]  L. Capelle,et al.  Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. , 2006, Neuro-oncology.

[215]  H. Hackstein,et al.  TLR7 ligands induce higher IFN-alpha production in females. , 2006, Journal of immunology.

[216]  M. de Bandt Lessons for lupus from tumour necrosis factor blockade. , 2006, Lupus.

[217]  R. Ashman,et al.  TLR-9 Activation of Marginal Zone B Cells in Lupus Mice Regulates Immunity Through Increased IL-10 Production , 2005, Journal of Clinical Immunology.

[218]  N. Demaurex,et al.  Endosome-to-cytosol transport of viral nucleocapsids , 2005, Nature Cell Biology.

[219]  K. Elkon,et al.  Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity , 2005 .

[220]  L. Klareskog,et al.  Oligodeoxynucleotides containing CpG motifs can induce T cell-dependent arthritis in rats. , 2004, Arthritis and rheumatism.

[221]  J. Delattre,et al.  CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. , 2003, Frontiers in bioscience : a journal and virtual library.

[222]  M. Crow Interferon-alpha: a new target for therapy in systemic lupus erythematosus? , 2003, Arthritis and rheumatism.

[223]  A. Krieg,et al.  CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. , 2003, Journal of immunology.

[224]  A. Krieg,et al.  CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.

[225]  R. Steinman Inaugural Article : avoiding horror autotoxicus. The importance of dendritic cells in peripheral T cell tolerance , 2002 .

[226]  V. Hornung,et al.  Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. , 2001, European journal of immunology.

[227]  V. Pascual,et al.  Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. , 2001, Science.

[228]  U. Båve,et al.  The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. , 2000, Journal of immunology.

[229]  A. Krieg,et al.  Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus , 1999 .

[230]  A. Krieg Direct Immunologic activities of CpG DNA and implications for gene therapy , 1999, The journal of gene medicine.